Iraq sits on an estimated 115 billion barrels of oil theworld's third largest reservesAbout Measurement Specialties Measurement Specialties Inc2 Texas 20 vs Texas Tech 20 Line Texas 17The secondary market allowsinvestors in funds to sell their stakesMike Kenn was a monster of a pass blockersubsegment 16 million in the Global NonU is one of thenation's leading auctioneers They might still be in the hunt for the Wild Cardbased company to compete lawfully with local competitorsThe Corporation distributed a total of 40(Nasdaq:CYCC) (Nasdaq:CYCCP) announced today that itsPresident and Chief Executive Officer, Spiro Rombotis, will present at theEleventh Annual BIO CEO & Investor Conference taking place in New York onFebruary 9-10, 2009. Cyclacel's presentation will take place on Monday, February9 at 9:30 a.m. Eastern.Cyclacel's presentation will be webcast live and archived for 90 days on theCorporate Presentations page of the Cyclacel website at Cyclacel Pharmaceuticals, Inc.Cyclacel is a biopharmaceutical company dedicated to the discovery, developmentand commercialization of novel, mechanism-targeted drugs to treat human cancersand other serious disorders. Three orally-available Cyclacel drugs are inclinical development. Sapacitabine (CYC682), a cell cycle modulating nucleosideanalog, is in Phase 2 studies for the treatment of acute myeloid leukemia in theelderly, myelodysplastic syndromes, cutaneous T-cell lymphoma and lung cancer.Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor,is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer.CYC116, an Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in patients withsolid tumors. Cyclacel's ALIGN Pharmaceuticals subsidiary markets directly inthe U.S. 
Xclair(R) Cream for radiation dermatitis, Numoisyn(R) Liquid andNumoisyn(R) Lozenges for xerostomia. Note: The Cyclacellogo and Cyclacel(R) are trademarks of Cyclacel Pharmaceuticals, Inc.Numoisyn(R) and Xclair(R) are trademarks of Sinclair Pharma plc.Risk FactorsThis news release contains certain forward-looking statements that involve risksand uncertainties that could cause actual results to be materially differentfrom historical results or from any future results expressed or implied by suchforward-looking statements. Such forward-looking statements include statementsregarding, among other things, the efficacy, safety, and intended utilization ofCyclacel's product candidates, the conduct and results of future clinicaltrials, plans regarding regulatory filings, future research and clinical trialsand plans regarding partnering activities. Factors that may cause actual resultsto differ materially include the risk that product candidates that appearedpromising in early research and clinical trials do not demonstrate safety and/orefficacy in larger-scale or later clinical trials, the risk that Cyclacel willnot obtain approval to market its products, the risks associated with relianceon outside financing to meet capital requirements, and the risks associated withreliance on collaborative partners for further clinical trials, development andcommercialization of product candidates.
You are urged to consider statementsthat include the words "may," "will," "would," "could," "should," "believes,""estimates," "projects," "potential," "expects," "plans," "anticipates,""intends," "continues," "forecast," "designed," "goal," or the negative of thosewords or other comparable words to be uncertain and forward-looking. Thesefactors and others are more fully discussed under "Risk Factors" in the AnnualReport on Form 10-K for the year ended December 31, 2007, as supplemented by theinterim quarterly reports, filed with the SEC.-0-CONTACT:Cyclacel Pharmaceuticals, Inc.Corey Sohmer(908) 517-7330WeissComm PartnersAline Schimmel(312) 646-6295College Hill, Life SciencesSue CharlesJustine Lamond44 (20) 7866 7857. ) After the Red Wings’ failure to capture a second Stanley Cup in a row this past summer, I think there are several questions that are brought to the attention for this upcoming season.? Are the wings still going to have the drive that took them to the finals two years in a row? Can the defense be better than it was last year? How will thegoal-tending be this year? How has the departure of Hossa and Hudler really hurt the team? Will the acquisitions the Wings’ have made over the summer, actually be beneficial? Of all of the newcomers, who will step up? These are the main questions, amongst many others, that the Wings’ have to face this upcoming season.There is question that the Red Wings might be tired, and just might not have the drive to continue having strong seasons and playoff runs.? That is possible, but look at it another way.? Last season, even though the Red Wings got to the finals, that was their championship hangover year.? ? Many players had bad years, including: Osgood; Zetterberg; Cleary; Filpulla; even Lidstrom.? Then to lose in game seven in Detroit was heartbreaking, so I think the Wings have a lot to play for to prove they still have what it takes to be a top contender.? The Wings still have all the key players; they’re still a tight group.? Yes, they lost some goals with Hossa and Hudler leaving but this now allows other players to step up to score.? Like I said, a lot of players had bad, low scoring seasons; this is their chance to make up for their lackluster performances.? Even though a couple players left, this is still pretty much the same group that won the Stanley Cup the year before…which Hossa wasn’t a part of.? I don’t understand why the Wings are counted out now that he left, when they won it the year before without him.? What needs to be seen is that the defense can get on track.? It was terrible last year.? Everyone was all over the place, I don’t know if that was because of poor coaching or the players were just doing poorly but that needs to be fixed.? The Wings NEED solidgoal-tending.? They received it in the postseason, but you can’t get there without having a solid regular season.? The Wings need players to step up this year, put that extra effort in to finish plays and score goals.? In the weeks to come we will see who and what the Wings have to work with.? We will see which goaltenders will stay.? Will Cloutier turn is career around with the team that “destroyed” it? We know what the guys from Grand Rapids are capable of, so let’s see how well they do when they’re with the team the whole season.? Personally I have a feeling that Leino will be a breakout star.? He is tough to knock off the puck, has a great shot, and great hands.? I think he could be as good as Hossa if not better.? In the upcoming weeks, the Wings will see which lines work best together… can Williams produce in his second time around with the Wings? Will Eaves be the next Cleary? Does Bertuzzi still have it in him to play tough and score goals? Will Datsyuk finally make it to 100 points or beyondThere are quite a few questions surrounding the Red Wings at the moment, and only time will tell when and what the answers will be.. Sussex Bancorp Announces 2008 Results of Operations; Operations Reflect Impactof Charge for Fannie Mae and Freddie Mac SecuritiesFRANKLIN, N.J., Feb. The Company's performance in 2008primarily reflects the effect of a $3.5 million other than temporary impairmentcharge recognized by the Company in the third quarter in connection with certainFannie Mae and Freddie Mac perpetual preferred stock held by the Company.
